Fluence

Fluence is a New York-based neurotechnology and education company specializing in psychedelic-assisted psychotherapy training for licensed mental health professionals. The company develops and delivers accredited continuing education curricula focused on ketamine and emerging psychedelic therapies, equipping clinicians with the clinical frameworks, ethical grounding, and practical skills needed to safely administer these treatments. Fluence's programs span foundational to advanced levels, addressing preparation, facilitation, and integration phases of psychedelic therapy. Their training is designed to meet the growing demand for credentialed practitioners as psychedelic medicine moves closer to mainstream clinical adoption.

Fluence has established itself as one of the most recognized and widely adopted psychedelic therapy training organizations in North America, with its curriculum accepted across a broad network of healthcare institutions, clinics, and private practices. As a bootstrapped organization, the company has achieved significant reach and credibility without relying on external venture funding, demonstrating strong organic demand for its educational offerings. Their accreditation status gives the curriculum formal standing within continuing education frameworks, lending institutional legitimacy to a field that has historically lacked standardized training pathways. Fluence has played a meaningful role in scaling the clinical workforce at a critical inflection point for the psychedelic medicine industry.

Fluence matters to the neurotech industry because it addresses one of the most significant bottlenecks to psychedelic therapy adoption: the shortage of properly trained clinicians. As compounds like MDMA, psilocybin, and ketamine advance through regulatory pipelines, the absence of standardized practitioner training represents a systemic risk to safe and scalable deployment. Fluence effectively bridges the gap between clinical research breakthroughs and real-world therapeutic implementation. By professionalizing the practitioner layer of the psychedelic ecosystem, the company contributes directly to the infrastructure that will determine how responsibly and effectively these powerful treatments reach patients.